Table 3.
Summary of clinical features cases with MYC amplification.
| Clinical featuresa | |
|---|---|
| Age at diagnosis, median (range), years | 66 (25–88) |
| Male: Female | 1.4: 1 |
| Bone marrow involvement | 1/21 (5%) |
| Other extranodal site involvement | 28/31 (90%) |
| Gastrointestinal | 10/31 (32%) |
| Timepoint of sample studied with MYC amp | |
| Initial diagnosis | 26/31 (84%) |
| Relapse | 5/31 (16%) |
| LDH, median (range), U/L | 314 (143–3942) |
| First line R-CHOP | 17/26 (65%) |
| Duration of follow-up, median (95% CI), months | 27.9 (18.4–45.6) |
| Deaths | 16 (44%) |
| Cause of death-lymphoma relapse | 10/16 (62%) |
aN = 44 for age and M:F; N = 36 for other clinical parameters unless otherwise specified